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Updating of systematic reviews is 
generally more efficient than starting 
all over again when new evidence 
emerges, but to date there has been 
no clear guidance on how to do this. 
This guidance helps authors of 
systematic reviews, commissioners, 
and editors decide when to update a 
systematic review, and then how to 
go about updating the review.
Systematic reviews synthesise relevant research around 
a particular question. Preparing a systematic review is 
time and resource consuming, and provides a snapshot 
of knowledge at the time of incorporation of data from 
studies identified during the latest search. Newly iden-
tified studies can change the  conclusion of a review. If 
they have not been included, this threatens the validity 
of the review, and, at worst, means the review could 
mislead. For patients and other healthcare consumers, 
this means that care and policy development might not 
be fully informed by the latest research; furthermore, 
researchers could be misled and carry out research in 
areas where no further research is actually needed.1 
Thus, there are clear benefits to updating reviews, 
rather than duplicating the entire process as new evi-
dence emerges or new methods develop. Indeed, there 
is probably added value to updating a review, because 
this will include taking into account comments and crit-
icisms, and adoption of new methods in an iterative 
process.2-6
Cochrane has over 20 years of experience with pre-
paring and updating systematic reviews, with the 
publication of over 6000 systematic reviews. How-
ever, Cochrane’s principle of keeping all reviews up to 
date has not been possible, and the organisation has 
had to adapt: from updating when new evidence 
becomes available,7  to updating every two years,8  to 
updating based on need and priority.9 This experience 
has shown that it is not possible, sensible, or feasible 
Summary pointS
Updating systematic reviews is, in general, more efficient than starting afresh when new evidence emerges. The panel for updating guidance 
for systematic reviews (PUGs; comprising review authors, editors, statisticians, information specialists, related methodologists, and guideline 
developers) met to develop guidance for people considering updating systematic reviews. The panel proposed the following:
1. Decisions about whether and when to update a systematic review are judgments made for individual reviews at a particular time. These 
decisions can be made by agencies responsible for systematic review portfolios, journal editors with systematic review update services, or 
author teams considering embarking on an update of a review.
2. The decision needs to take into account whether the review addresses a current question, uses valid methods, and is well conducted; and 
whether there are new relevant methods, new studies, or new information on existing included studies. Given this information, the agency, 
editors, or authors need to judge whether the update will influence the review findings or credibility sufficiently to justify the effort in updating it.
3. Review authors and commissioners can use a decision framework and checklist to navigate and report these decisions with “update status” 
and rationale for this status. The panel noted that the incorporation of new synthesis methods (such as Grading of Recommendations 
Assessment, Development and Evaluation (GRADE)) is also often likely to improve the quality of the analysis and the clarity of the findings.
4. Given a decision to update, the process needs to start with an appraisal and revision of the background, question, inclusion criteria, and 
methods of the existing review.
5. Search strategies should be refined, taking into account changes in the question or inclusion criteria. An analysis of yield from the previous 
edition, in relation to  databases searched, terms, and languages can make searches more specific and efficient.
6. In many instances, an update represents a new edition of the review, and authorship of the new version needs to follow criteria of the 
International Committee of Medical Journal Editors (ICMJE). New approaches to publishing licences could help new authors build on and 
re-use the previous edition while giving appropriate credit to the previous authors.
The panel also reflected on this guidance in the context of emerging technological advances in software, information retrieval, and electronic 
linkage and mining. With good synthesis and technology partnerships, these advances could revolutionise the efficiency of updating in the 
coming years. 
 o
n
 12 N
ovem
ber 2018 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.i3507 on 20 July 2016. Downloaded from 
doi: 10.1136/bmj.i3507 | BMJ 2016;354:i3507 | the bmj
ReseaRch Methods and RepoRting
2
to continually update all reviews all the time. Other 
groups, including guideline developers and journal 
editors, adopt updating principles (as applied, for 
example, by the Systematic Reviews journal;  https://
systematicreviewsjournal.biomedcentral.com/). 
The panel for updating guidance for systematic 
reviews (PUGs) group met to draw together experiences 
and identify a common approach. The PUGs guidance 
can help individuals or academic teams working out-
side of a commissioning agency or Cochrane, who are 
considering writing a systematic review for a journal or 
to prepare for a research project. The guidance could 
also help these groups decide whether their effort is 
worthwhile.
panel selection and procedures
An international panel of authors, editors, clinicians, 
statisticians, information specialists, other method-
ologists, and guideline developers was invited to a 
two day workshop at McMaster University, Hamilton, 
Canada, on 26-27 June 2014, organised by Cochrane. 
The organising committee selected the panel (web 
appendix 1). The organising committee invited par-
ticipants, put forward the agenda, collected back-
ground materials and literature, and drafted the 
structure of the report.
The purpose of the workshop was to develop a com-
mon approach to updating systematic reviews, drawing 
on existing strategies, research, and experience of peo-
ple working in this area. The selection of participants 
aimed on broad representation of different groups 
involved in producing systematic reviews (including 
authors, editors, statisticians, information specialists, 
and other methodologists), and those using the reviews 
(guideline developers and clinicians). Participants 
within these groups were selected on their expertise 
and experience in updating, in previous work develop-
ing methods to assess reviews, and because some were 
recognised for developing approaches within organisa-
tions to manage updating strategically. We sought to 
identify general approaches in this area, and not be 
specific to Cochrane; although inevitably most of the 
panel were somehow engaged in Cochrane.
The workshop structure followed a series of short 
presentations addressing key questions on whether, 
when, and how to update systematic reviews. The pro-
ceedings included the management of authorship and 
editorial decisions, and innovative and technological 
approaches. A series of small group discussions fol-
lowed each question, deliberating content, and forming 
recommendations, as well as recognising uncertainties. 
Large group, round table discussions deliberated fur-
ther these small group developments. Recommenda-
tions were presented to an invited forum of individuals 
with varying levels of expertise in systematic reviews 
from McMaster University (of over 40 people), widely 
known for its contributions to the field of research evi-
dence synthesis. Their comments helped inform the 
emerging guidance.
The organising committee became the writing com-
mittee after the meeting. They developed the guidance 
arising from the meeting, developed the checklist and 
diagrams, added examples, and finalised the manu-
script. The guidance was circulated to the larger group 
three times, with the PUGs panel providing extensive 
feedback. This feedback was all considered and care-
fully addressed by the writing committee. The writing 
committee provided the panel with the option of 
expressing any additional comments from the general 
or specific guidance in the report, and the option for 
registering their own view that might differ to the guid-
ance formed and their view would be recorded in an 
annex. In the event, consensus was reached, and the 
annex was not required.
Definition of update
The PUGs panel defined an update of a systematic 
review as a new edition of a published systematic 
review with changes that can include new data, new 
methods, or new analyses to the previous edition. This 
expands on a previous definition of a systematic 
review update.10 An update asks a similar question 
with regard to the participants, intervention, compar-
isons, and outcomes (PICO) and has similar objectives; 
thus it has similar inclusion criteria. These inclusion 
criteria can be modified in the light of developments 
within the topic area with new interventions, new 
standards, and new approaches. Updates will include 
a new search for potentially relevant studies and 
incorporate any eligible studies or data; and adjust the 
findings and conclusions as appropriate. Box 1 pro-
vides some examples.
Which systematic reviews should be updated and when?
Any group maintaining a portfolio of systematic reviews 
as part of their normative work, such as guidelines pan-
els or Cochrane review groups, will need to prioritise 
which reviews to update. Box 2 presents the approaches 
used by the Agency for HealthCare Research and Qual-
ity (AHRQ) and Cochrane to prioritise which systematic 
reviews to update and when. Clearly, the responsibility 
for deciding which systematic reviews should be 
updated and when they will be updated will vary: it 
may be centrally organised and resourced, as with the 
AHRQ scientific resource centre (box 2). In Cochrane, 
the decision making process is decentralised to the 
Cochrane Review Group editorial team, with different 
approaches applied, often informally.
Box 1: Examples of what factors might change in an updated systematic review
•	A systematic review of steroid treatment in tuberculosis meningitis used GRADE 
methods and split the composite outcome in the original review of death plus 
disability into its two components. This improved the clarity of the reviews findings 
in relation to the effects and the importance of the effects of steroids on death and 
on disability.11
•	A systematic review of dihydroartemisinin-piperaquine (DHAP) for treating malaria 
was updated with much more detailed analysis of the adverse effect data from the 
existing trials as a result of questions raised by the European Medicines Agency. 
Because the original review included other comparisons, the update required 
extracting only the DHAP comparisons from the original review, and a modification 
of the title and the PICO.12
•	A systematic review of atorvastatin was updated with simple uncontrolled studies.13  
This update allowed comparisons with trials and strengthened the review findings.14
 o
n
 12 N
ovem
ber 2018 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.i3507 on 20 July 2016. Downloaded from 
the bmj | BMJ 2016;354:i3507 | doi: 10.1136/bmj.i3507
ReseaRch Methods and RepoRting
3
The PUGs panel recommended an individualised 
approach to updating, which used the procedures 
 summarised in figure 1 . The figure provides a status cat-
egory, and some options for classifying reviews into each 
of these categories, and builds on a previous decision 
tool and earlier work developing an updating classifica-
tion system.15 16 We provide a narrative for each step.
Step 1: assess currency
Does the published review still address a current 
question?
An update is only worthwhile if the question is topical 
for decision making for practice, policy, or research pri-
orities (fig 1). For agencies, people responsible for man-
aging a portfolio of systematic reviews, there is a need 
to use both formal and informal horizon scanning. 
This type of scanning helps identify questions with cur-
rency, and can help identify those reviews that should 
be updated. The process could include monitoring 
 policy debates around the review, media outlets, 
 scientific (and professional) publications, and linking 
with guideline developers.
Has the review had good access or use?
Metrics for citations, article access and downloads, 
and sharing via social or traditional media can be used 
as proxy or indicators for currency and relevance of 
the review. Reviews that are widely cited and used 
could be important to update should the need arise. 
Comparable reviews that are never cited or rarely 
downloaded, for example, could indicate that they are 
not addressing a question that is valued, and might 
not be worth updating.
In most cases, updated reviews are most useful to 
stakeholders when there is new information or meth-
ods that result in a change in findings. However, 
there are some circumstances in which an up to date 
search for information is important for retaining 
the credibility of the review, regardless of whether the 
main findings would change or not. For example, key 
stakeholders would dismiss a review if a study is 
 carried out in a relevant geographical setting but is 
not included; if a large, high profile study that might 
not change the findings is not included; or if an up to 
date search is required for a guideline to achieve cred-
ibility. Box 3 provides such examples. If the review 
does not answer a current question, the intervention 
has been superseded, then a decision can be made 
not to update and no further intelligence gathering is 
required (fig 1).
Did the review use valid methods and was it well 
conducted?
If the question is current and clearly defined, the sys-
tematic review needs to have used valid methods and 
be well conducted. If the review has vague inclusion 
criteria, poorly articulated outcomes, or inappropriate 
methods, then updating should not proceed. If the 
question is current, and the review has been cited or 
used, then it might be appropriate to simply start with a 
new protocol. The appraisal should take into account 
the methods in use when the review was done.
Step 2: identify relevant new methods, studies, and 
other information
Are there any new relevant methods?
If the question is current, but the review was done some 
years ago, the quality of the review might not meet cur-
rent day standards. Methods have advanced quickly, 
and data extraction and understanding of the review 
process have become more sophisticated. For example:
•	 Methods for assessing risk of bias of randomised 
 trials,23  diagnostic test accuracy (QUADAS-2),24  and 
observational studies (ROBINS-1).25
•	 Application of summary of findings, evidence pro-
files, and related GRADE methods has meant the 
characteristics of the intervention, characteristics of 
the participants, and risk of bias are more thoroughly 
and systematically documented.26 27
•	 Integration of other study designs containing evi-
dence, such economic evaluation and qualitative 
research.28
There are other incremental improvements in a wide 
range of statistical and methodological areas, for exam-
ple, in describing and taking into account cluster 
Box 2: Examples of how different organisations decide on updating systematic reviews
Agency for Healthcare Research and Quality (US)
The AHRQ uses a needs based approach; updating systematic reviews depends on an 
assessment of several criteria:
1. Stakeholder impact
•	 Interest from stakeholder partners (such as consumers, funders, guideline 
developers, clinical societies, James Lind Alliance)
•	 Use and uptake (for example, frequency of citations and downloads)
•	 Citation in scientific literature including clinical practice guidelines
2. Currency and need for update
•	 New research is available
•	 Review conclusions are probably dated
3. Update decision
•	 Based on the above criteria, the decision is made to either update, archive, or 
continue surveillance.
Cochrane
Of over 50 Cochrane editorial teams, most but not all have some systems for 
updating, although this process can be informal and loosely applied. Most editorial 
teams draw on some or all of the following criteria:
1. Strategic importance
•	 Is the topic a priority area (for example, in current debates or considered by 
guidelines groups)?
•	 Is there important new information available?
2. Practicalities in organising the update that many groups take into account
•	 Size of the task (size and quality of the review, and how many new studies or 
analyses are needed)
•	 Availability and willingness of the author team
3. Impact of update
•	 New research impact on findings and credibility
•	 Consider whether new methods will improve review quality
4. Update decision
•	 Priority to update, postpone update, class review as no longer requiring an update
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 randomised trials.29  AMSTAR can assess the overall 
quality of a systematic review,30  and the ROBIS tool can 
provide a more detailed assessment of the potential 
for bias.31
Are there any new studies or other information?
If an authoring or commissioning team wants to ensure 
that a particular review is up to date, there is a need for 
routine surveillance for new studies that are potentially 
relevant to the review, by searching and trial register 
inspection at regular intervals. This process has several 
approaches, including:
•	 Formal surveillance searching32
•	 Updating the full search strategies in the original 
review and running the searches
•	 Tracking studies in clinical trial and other registers
•	 Using literature appraisal services33
•	 Using a defined abbreviated search strategy for the 
update34
•	 Checking studies included in related systematic 
reviews.35
How often this surveillance is done, and which 
approaches to use, depend on the circumstances and 
the topic. Some topics move quickly, and the definition 
of “regular intervals” will vary according to the field 
and according to the state of evidence in the field. For 
example, early in the life of a new intervention, there 
might be a plethora of studies, and surveillance would 
be needed more frequently.
Step 3: assess the effect of updating the review
Will the adoption of new methods change the 
findings or credibility?
Editors, referees, or experts in the topic area or meth-
odologists can provide an informed view of whether a 
review can be substantially improved by application 
of current methodological expectations and new 
methods (fig 1 ). For example, a Cochrane review of 
iron supplementation in malaria concluded that there 
was “no significant difference between iron and pla-
cebo detected.”36  An update of the review included a 
GRADE assessment of the certainty of the evidence, 
and was able to conclude with a high degree of cer-
tainty that iron does not cause an excess of clinical 
malaria because the upper relative risk confidence 
intervals of harm was 1.0 with high certainty of 
 evidence.37
Will the new studies, information, or data change 
the findings or credibility?
The assessment of new data contained in new studies 
and how these data might change the review is often 
used to determine whether an update should go ahead, 
Box 3: Examples of a systematic review’s currency
•	The public is interested in vitamin C for preventing the common cold: the Cochrane 
review includes over 29 trials with either no or small effects, concluding good 
evidence of no important effects.17 Assessment: still a current question for the public.
•	Low osmolarity oral rehydration salt (ORS) solution versus standard solution for 
acute diarrhoea in children: the 2001 Cochrane review18  led the World Health 
Organization to recommend ORS solution formula worldwide to follow the new ORS 
solution formula19 and this has now been accepted globally. Assessment: no longer 
a current question.
•	Routine prophylactic antibiotics with caesarean section: the Cochrane review 
reports clear evidence of maternal benefit from placebo controlled trials but no 
information on the effects on the baby.20 Assessment: this is a current question.
•	A systematic review published in the Lancet examined the effects of artemisinin 
based combination treatments compared with monotherapy for treating malaria 
and showed clear benefit.21 Assessment: this established the treatment globally 
and is no longer a current question and no update is required.
•	A Cochrane review of amalgam restorations for dental caries22 is unlikely to be 
updated because the use of dental amalgam is declining, and the question is not 
seen as being important by many dental specialists. Assessment: no longer a 
current question.
Does published review still address a
current question? Has review had good
access or use? Review used valid
methods and was well conducted?
Intervention(s) not in (general) use or been
  superseded
Research superseded
Research area no longer active
Low impact of published version (eg, via article
  level metrics)
Other (provide reason)
Update status Rationale for update status
No update planned
No
Yes
Are there any new relevant methods? Are
there any new studies, or new information?
No new studies identied with search
All studies incorporated from most recent search
Potentially relevant studies ongoing but not
  complete
Other (provide reason)
Authors currently updating
Studies awaiting assessment
New contributors needed
Other (provide reason)
Up to date
No
Yes
Will adoption of new methods
change ndings or credibility?
Will new studies/information/data
change ndings or credibility?
Prepare update
Certainty (quality) of evidence high in published
  review
New information identied but unlikely to change
  review ndings
Other (provide reason)
Up to date
No
Update pending
Yes or maybe
Fig 1 | Decision framework to assess systematic reviews for updating, with standard terms to report such decisions
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and the speed with which the update should be con-
ducted. The appraisal of these new data can be carried 
out in different ways. Initially, methods focused on sta-
tistical approaches to predict an overturning of the cur-
rent review findings in terms of the primary or desired 
outcome (table 1). Although this aspect is important, 
additional studies can add important information to a 
review, which is more than just changing the primary 
outcome to a more accurate and reliable estimate. 
Box 4 gives examples.
Reviews with a high level of certainty in the results 
(that is, when the GRADE assessment for the body of evi-
dence is high) are less likely to change even with the 
addition of new studies, information, or data, by defini-
tion. GRADE can help guide priorities in whether to 
update, but it is still important to assess new studies 
that might meet the inclusion criteria. New studies can 
show unexpected effects (eg, attenuation of efficacy) or 
provide new information about the effects seen in differ-
ent circumstances (eg, groups of patients or locations).
Other tools are specifically designed to help decision 
making in updating. For example, the Ottawa39  and 
RAND45  methods focus on identification of new 
 evidence, the statistical predication tool15  calculates 
the probability of new evidence changing the review 
conclusion, and the value of information analysis 
approach52  calculates the expected health gain (table 1). 
As yet, there has been limited external validation of 
these tools to determine which approach would be most 
effective and when.
If potentially relevant studies are identified that have 
not previously been assessed for inclusion, authors or 
those managing the updating process need to assess 
whether including them might affect the conclusions of 
the review. They need to examine the weight and cer-
tainty of the new evidence to help determine whether 
an update is needed and how urgent that update is. The 
updating team can assess this informally by judging 
whether new studies or data are likely to substantively 
affect the review, for example, by altering the certainty 
in an existing comparison, or by generating new com-
parisons and analyses in the existing review.
New information can also include fresh follow-up 
data on existing included studies, or information on 
how the studies were carried out. These should be 
assessed in terms of whether they might change the 
review findings or improve its credibility (fig 1). 
Indeed, if any study has been retracted, it is important 
the authors assess the reasons for its retraction. In the 
case of data fabrication, the study needs to be removed 
Box 4: Examples of new information other than new trials being important
•	The iconic Cochrane review of steroids in preterm labour was thought to provide 
evidence of benefit in infants, and this question no longer required new trials. 
However, a new large trial published in the Lancet in 2015 showed that in low 
and middle income countries, strategies to promote the uptake of neonatal 
steroids increased neonatal mortality and suspected maternal infection.49 This 
information needs to somehow be incorporated into the review to maintain its 
credibility.
•	A Cochrane review of community deworming in developing countries indicates 
that in recent studies, there is little or no effect.50 The inclusion of a large trial of 
two million children confirmed that there was no effect on mortality. Although the 
incorporation of the trial in the review did not change the review’s conclusions, 
the trial’s absence would have affected the credibility of the review, so it was 
therefore updated.
•	A new paper reporting long term follow-up data on anthracycline chemotherapy 
as part of cancer treatment was published. Although the effects from the 
outcomes remained essentially unchanged, apart from this longer follow-up, the 
paper also included information about the performance bias in the original trial, 
shifting the risk of bias for several outcomes from “unknown” to “high” in the 
Cochrane review.51
Table 1 | Formal prediction tools: how potentially relevant new studies can affect review conclusions 
Method Description of approach How it could be used Advantages Limitations Validation
GRADE 
approach38
Considers whether the evidence certainty might change in 
the update (for example, because of lack of high certainty 
evidence, or because new evidence contradicts existing 
high certainty evidence). High certainty of evidence for 
critical outcomes could lower the priority for updating. 
Uncertainty in the review findings increases the need to 
include new studies38
Provides a benchmark 
by outcome to assess 
whether a new trial 
will improve the 
certainty of the 
evidence
Pragmatic. 
Many reviews 
already 
include 
GRADE
Requires GRADE to 
have been used in 
existing review or to 
complete an 
assessment 
according to GRADE
GRADE summary of findings 
tables or evidence profiles 
widely validated.
Use of GRADE approach to 
prioritising updates requires 
further validation
Ottawa 
method39-41
A simple PubMed search (using the three largest and three 
most recent trials from the original review) to identify new 
studies. If new studies are found, then the method uses 
quantitative signals (eg, change in significance, effect size) 
to assess the likelihood that the new studies will change 
the review conclusion, thus triggering an update
Practical routine 
surveillance tool
Easy to use Will not detect all 
trials; judgment 
only based on 
changing 
conclusion
Approach validated for 
consistency of predicted and 
actual changes to conclusions; 
reasonable agreement with 
RAND method3942-44
RAND 
method45
An abbreviated search of five major journals to identify new 
studies, and a search of the US Food and Drug 
Administration website and external expert judgment to 
determine the currency of the report findings
Practical routine 
surveillance tool
Easy to use Will not detect all 
trials; judgment 
only based on 
changing 
conclusion
Approach validated for 
consistency of predicted and 
actual changes to conclusions, 
and compares well with the 
Ottawa method394344
Statistical 
prediction 
tool15
A multicomponent decision tool to assess whether there 
might be any new studies for the update. If new studies are 
identified, a statistical prediction tool estimates the 
probability that this will change the review conclusion
Ranks multiple 
systematic reviews in 
order of priority for 
updating
Uses 
quantitative 
approach
More complicated; 
requires commercial 
software
Approach validated 
internally46; requires further 
external validation
Value of 
information 
analysis47 48
Builds on the statistical prediction tool approach15 
comparing the expected health gain from new evidence 
with its expected cost. The gain is calculated in terms of a 
reduction in expected loss from reduced uncertainty and 
the cost is measured in days required to update the 
review.
Ranks selected 
systematic reviews in 
order of priority for 
updating
Uses 
quantitative 
approach
More complicated; 
requires some 
statistical 
knowledge
Approach validated internally; 
requires further external 
validation
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from the analysis and this recorded. A decision needs 
to be made as to whether other studies by the same 
author should be removed from the review and other 
related reviews. An investigation should also be 
 initiated following guidelines from the Committee on 
Publication Ethics (COPE). Additional published and 
unpublished data can become available from a wide 
range of sources—including study investigators, regu-
latory agencies and industry—and are important to 
consider.
preparing for an update
Refresh background, objectives, inclusion criteria, 
and methods
Before including new studies in the review, authors 
need to revisit the background, objectives, inclusion 
criteria, and methods of the current review. In 
Cochrane, this is referred to as the protocol, and editors 
are part of this process. The update could range from 
simply endorsing the current question and inclusion 
criteria, through to full rewriting of the question, inclu-
sion criteria and methods, and republishing the proto-
col. As a field progresses with larger and better quality 
trials rigorously testing the questions posed, it may be 
appropriate to exclude weaker study designs (such as 
quasi-randomised comparisons or very small trials) 
from the update (table 2). The PUGs panel recom-
mended that a protocol refresh will require the authors 
to use the latest accepted methods of synthesis, even if 
this means repeating data extraction for all studies.
New authors and authorship
Updated systematic reviews are new publications with 
new citations. An authorship team publishing an 
update in a scientific or medical journal is likely to 
 manage the new edition of a review in the same way as 
with any other publication, and follow the ICMJE 
authorship criteria.56 If the previous author or author 
team steps down, then they should be acknowledged in 
the new version. However, some might perceive that 
their efforts in the first version warrant continued 
authorship, which may be valid. The management 
of  authorship between versions can sometimes be 
 complicated. At worst, it delays new authors complet-
ing an update and leads to long authorship lists of peo-
ple from previous versions who probably do not meet 
ICMJE authorship criteria. One approach with updates 
including new authors is to have an opt-in policy for the 
existing authors: they can opt in to the new edition, pro-
vided that they make clear their contribution, and this 
is then agreed with the entire author team.
Although they are new publications, updates will 
generally include content from the published version. 
Changing licensing rights around systematic reviews to 
allow new authors of future updates to remix, tweak, or 
build on the contributions of the original authors of the 
published version (similar to the rights available via a 
Creative Commons licence; https://creativecommons.
org) could be a more sustainable and simpler approach. 
This approach would allow systematic reviews to con-
tinue to evolve and build on the work of a range of 
authors over time, and for contributors to be given 
credit for contributions to this previous work.
Efficient searching
In performing an update, a search based on the search 
conducted for the original review is required. The 
updated search strategy will need to take into account 
changes in the review question or inclusion criteria, for 
example, and might be further adjusted based on 
knowledge of running the original search strategy. 
The search strategy for an update need not replicate the 
original search strategy, but could be refined, for exam-
ple, based on an analysis of the yield of the original 
search. These new search approaches are currently 
undergoing formal empirical evaluation, but they may 
well provide much more efficient search strategies in 
the future. Some examples of these possible new meth-
ods for review updates are described in web appendix 2.
In reporting the search process for the update, investi-
gators must ensure transparency for any previous ver-
sions and the current update, and use an adapted flow 
diagram based on PRISMA reporting (preferred reporting 
items for systematic reviews and meta-analyses).57 The 
search processes and strategies for the update must be 
adequately reported such that they could be replicated.
Table 2 | Refresh background, objectives, inclusion criteria, and methods
Protocol section Appraisal points
Background and 
research question
•  Review and update background section, including supporting references to take account of any changes that may have occurred. This should include 
updating any new information and current policy debates on the topic.
• Assess whether the current review question remains relevant to patients and practice.
Inclusion criteria • Consider whether the existing PICO(s) remain(s) current, in the light of new knowledge.
• Identify any new understanding of definition of patient populations.
• Identify new interventions, or those that have been withdrawn, that are no longer in use.
• Identify any changes in usual care standards.
•  Check for standardised core outcomes sets, such as those developed in collaboration with the core outcome measures in effectiveness trials (COMET) 
initiative (www.comet-initiative.org) or by guideline groups since the original review.
• Check for any relevant patient reported outcomes to include subsequent to the original review.
•  Consider any new studies with less risk of bias that might warrant a stricter study design inclusion criteria (where the older version, when there was a 
dearth of evidence, included observational or quasi-randomised comparisons).
Methods •  Appraise and update the methods pending relevant methodological advancements or developments. For example, if (1) there are new tools for 
assessing the risk of bias of individual studies or appraising the quality of a body of evidence (eg, GRADE); or (2) new and efficient search approaches 
are feasible, such as a targeted approach to searching, taking into account the quality of the original search, and ensuring that the search for the 
update is of high quality.
•  Update or include a summary of findings table, which is recommended for all systematic reviews, because it improves the clarity, understanding, and 
interpretation of the findings of a systematic review, and rapidly reduces the amount of time readers require to find key information.53-55
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Peer review
Systematic reviews published for the first time in peer 
reviewed journals are by definition peer reviewed, but 
practice for updates remains variable, because an 
update might have few changes (such as an updated 
search but no new studies found and therefore 
included) or many changes (such as revise methods and 
inclusion of several new studies leading to revised 
 conclusions). Therefore, and to use peer reviewers’ time 
most effectively, editors need to consider when to peer 
review an update and the type of peer reviewer most 
useful for a particular update (for example, topic spe-
cialist, methodologist). The decision to use peer review, 
and the number and expertise of the peer reviewers 
could depend on the nature of the update and the 
extent of any changes to the systematic review as part of 
an editor assessment. A change in the date of the search 
only (where no new studies were identified) would not 
require peer review (except, arguably, peer review of the 
search), but the addition of studies that lead to a change 
in conclusions or significant changes to the methods 
would require peer review. The nature of the peer review 
could be described within the published article.
Reporting changes
Authors should provide a clear description of the 
changes in approach or methods between different 
 editions of a review. Also, authors need to report the dif-
ferences in findings between the original and updated 
edition to help users decide how to use the new edition. 
The approach or format used to present the differences 
in findings might vary with the target user group.58 Pub-
lishers need to ensure that all previous versions of the 
review remain publically accessible.
Updates can range from small adjustments to reviews 
being completely rewritten, and the PUGs panel spent 
some time debating whether the term “new edition” 
would be a better description than “update.” However, 
the word “update” is now in common parlance and 
changing the term, the panel judged, could cause con-
fusion. However, the debate does illustrate that an 
update could represent a review that asks a similar 
question but has been completely revised.
technology and innovation
The updating of systematic review is generally done 
manually and is time consuming. There are opportuni-
ties to make better use of technology to streamline the 
updating process and improve efficiency (table 3 ). 
Some of these tools already exist and are in develop-
ment or in early use, and some are commercially avail-
able or freely available. The AHRQ’s evidence based 
practice centre team has recently published tools for 
searching and screening, and will provide an assess-
ment of the use, reliability, and availability of these 
tools.63
Other developments, such as targeted updates that 
are performed rapidly and focus on updating only key 
components of a review, could provide different 
approaches to updating in the future and are being 
piloted and evaluated.64  With implementation of these 
various innovations, the longer term goal is for “living” 
systematic reviews, which identify and incorporate 
information rapidly as it evolves over time.60
Concluding remarks
Updating systematic reviews, rather than addressing 
the same question with a fresh protocol, is generally 
Table 3 | Technological innovations to improve the efficiency of updating systematic reviews
Innovation Description Application Examples of software and projects,* and current status
Integrated 
software
Integration of applying 
inclusion criteria, review 
management systems, 
statistical packages, and 
GRADE
To facilitate greater efficiencies in 
review production, including their 
updates
Covidence (www.covidence.org): free/pay†
EPPI reviewer (http://eppi.ioe.ac.uk/cms/Default.aspx): pay
DistillerSR (https://distillercer.com/products/distillersr-systematic-review-
software/): pay
Cochrane Review Manager (http://tech.cochrane.org/revman): free/pay†
GRADEpro GDT (http://gradepro.org/): free
Rayyan (http://rayyan.qcri.org/): free
Systematic review 
data repositories
Repositories store information 
from review (eg, data 
abstraction forms and the 
evidence tables)
Improve updating efficiency for new or 
existing teams as the data abstraction 
forms, evidence tables, and populating 
data from the original review are 
available
Agency of Health Care Research and Quality systematic review data 
repository (http://srdr.ahrq.gov): operational
GRADE database of evidence profiles and evidence to decision 
frameworks (http://dbep.gradepro.org/): operational
Semi-automation Machine learning techniques to 
use alongside human efforts
Finding studies and extracting data 
could benefit from semi-automation 
creating time efficiencies59
RobotReviewer (http://vortext.systems/robotreviewer): free
Cochrane project transform—identification of studies (http://community.
cochrane.org/tools/project-coordination-and-support/transform)
Crowdsourcing Use of volunteers to assist 
systematic review authors with 
discrete tasks
Individuals from the “crowd” assist with 
tasks (identifying and screening 
studies, translating articles, data 
extraction) to help in new review 
production and updates60-62
Cochrane Project Transform—crowdsourcing (link as above)
Publication 
linkage
Ability to link trial registration, 
trial publications, and reviews 
citing them will help 
transparency
This initiative could help identify studies 
for systematic reviews and could also 
show the relation between systematic 
review updates
A cross publisher initiative, CrossRef, is coordinating a threaded 
publications/linked clinical trial reports initiative to link a clinical trial 
report (with a trial registration number) report and derivative publications, 
including reviews (www.crossref.org): operational
Data linkage Increase links between data, 
existing software, and reviews
To improve identification and reuse of 
data for review production and 
dissemination
Cochrane (http://linkeddata.cochrane.org/): proof of principle example at 
production phase, but mostly linkage projects at exploratory phase
*Further information can be located on the SR Toolbox site (http://systematicreviewtools.com/).
†Free to Cochrane contributors; other users pay.
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more efficient and allows incremental improvement 
over time. Mechanical rules appear unworkable, but 
there is no clear unified approach on when to update, 
and how implement this. This PUGs panel of authors, 
editors, statisticians, information specialists, other 
methodologists, and guideline developers brought 
together current thinking and experience in this area to 
provide guidance.
Decisions about whether and when to update a sys-
tematic review are judgments made at a point in time. 
They depend on the currency of the question asked, the 
need for updating to maintain credibility, the availabil-
ity of new evidence, and whether new research or new 
methods will affect the findings.
Whether the review uses current methodological 
standards is important in deciding if the update will 
influence the review findings, quality, reliability, or 
credibility sufficiently to justify the effort in updating it. 
Those updating systematic reviews to author clinical 
practice guidelines might consider the influence of new 
study results in potentially overturning the conclusions 
of an existing review. Yet, even in cases where new 
study findings do not change the primary outcome mea-
sure, new studies can carry important information 
about subgroup effects, duration of treatment effects, 
and other relevant clinical information, enhancing the 
currency and breadth of review results.
An update requires appraisal and revision of the 
background, question, inclusion criteria, and methods 
of the existing review and the existing certainty in the 
evidence. In particular, methods might need to be 
updated, and search strategies reconsidered. Authors 
of updates need to consider inputs to the current edi-
tion, and follow ICMJE criteria regarding authorship.56
The PUGs panel proposed a decision framework 
(fig 1), with terms and categories for reporting the deci-
sions made for updating procedures for adoption by 
Cochrane and other stakeholders. This framework 
includes journals publishing systematic review updates 
and independent authors considering updates of exist-
ing published reviews. The panel developed a checklist 
to help judgements about when and how to update.
The current emphasis of authors, guideline develop-
ers, Cochrane, and consequently this guidance has 
been on effects reviews. The checklists and guidance 
here still applies to other types of systematic reviews, 
such as those on diagnostic test accuracy, and this 
guidance will need adapting. Accumulative experi-
ence and methods development in reviews other than 
those of effects are likely to help refine guidance in the 
future.
This guidance could help groups identify and priori-
tise reviews for updating and hence use their finite 
resources to greatest effect. Software innovation and 
new management systems are being developed and in 
early use to help streamline review updates in the com-
ing years.
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